Bristol myers squibb co (BMY)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash Flows From Operating Activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

3,460

4,947

975

4,507

1,631

2,029

2,580

2,501

5,260

4,513

11,862

6,243

2,928

Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings attributable to noncontrolling interest

-

-

-

-

-

-

17

541

1,551

1,411

1,250

996

763

Depreciation, Depletion and Amortization

1,746

637

789

382

376

467

763

681

628

607

-

-

-

Deferred Income Tax Expense (Benefit)

-924

45

453

-204

-347

-542

-491

-1,230

415

422

163

1,430

-416

Share-based Payment Arrangement, Noncash Expense

441

221

199

205

235

213

191

154

161

193

183

181

133

Impairment of Long-Lived Assets to be Disposed of

199

126

327

63

192

401

40

2,180

28

228

-

349

379

Depreciation

-

-

-

-

-

-

-

-

-

-

469

562

542

Amortization

-

-

-

-

-

-

-

-

-

-

238

254

350

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

32

230

Pension settlements and amortization

1,688

186

236

169

245

971

294

292

-

-

-

-

-

Divestiture gains and royalties

1,855

992

706

1,187

490

760

-

-

-

-

-

-

-

Asset acquisition charges

25

85

760

274

983

148

-

-

-

-

-

-

-

Equity investment, (gain) loss

279

-512

23

-37

-

-

-

-

-

-

-

-

-

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

523

0

0

-

-

-

-

-

-

-

-

-

-

Proceeds from Amylin diabetes alliance

-

-

-

-

-

-

-

3,570

-

-

135

61

454

Gain related to divestitures of discontinued operations

-

-

-

-

-

-

-

-

-

-

7,275

-3,412

0

Other Noncash Income (Expense)

22

44

-120

36

-15

21

9

35

147

32

367

158

223

Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Changes in operating assets and liabilities:
Gain on sale of ImClone shares

-

-

-

-

-

-

-

-

-

-

-

895

0

Increase (Decrease) in Receivables

-752

429

431

803

942

252

504

-648

220

270

-227

360

458

Increase (Decrease) in Inventories

-463

216

29

152

-97

254

45

103

193

-156

-82

-130

54

Increase (Decrease) in Accounts Payable

229

-59

320

104

-919

-44

412

-232

593

315

472

253

141

Deferred income

12

84

-642

-64

218

613

965

295

58

254

-

-

-

Increase (Decrease) in Income Taxes Payable

907

203

3,154

-453

194

171

126

-50

-134

-236

58

371

-199

Increase (Decrease) in Other Operating Assets and Liabilities, Net

-702

-634

227

-216

-617

-8

760

1,189

58

248

932

-338

-109

Net Cash Provided by (Used in) Operating Activities

8,067

5,940

5,275

3,058

2,105

3,148

3,545

6,941

4,840

4,491

4,065

3,707

3,153

Cash Flows From Investing Activities:
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale

3,809

2,379

6,398

4,809

2,794

4,095

1,815

4,890

5,960

3,197

2,075

560

20,634

Payments to Acquire Marketable Debt Securities

3,961

2,305

5,419

3,089

3,143

5,719

1,859

3,607

6,819

5,823

3,489

422

19,878

Payments to Acquire Property, Plant, and Equipment

836

951

1,055

1,215

820

526

537

548

367

424

730

941

843

Proceeds from Divestiture of Businesses, Net of Cash Divested

15,852

1,249

736

1,334

708

3,585

9

68

-

-

557

309

317

Proceeds from divestitures of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

4,530

0

Mead Johnson's cash at split-off

-

-

-

-

-

-

-

-

-

-

561

-

0

Payments to Acquire Businesses, Net of Cash Acquired

24,634

1,246

726

359

1,111

219

-

7,530

360

829

2,232

191

432

Other investing activities

-

-

-

-

-

-

-

-

-149

-67

-

-

-

Proceeds from sale of ImClone shares

-

-

-

-

-

-

-

-

-

-

-

1,007

0

Proceeds from sale and leaseback of properties

-

-

-

-

-

-

-

-

-

-

-

227

0

Net Cash Provided by (Used in) Investing Activities

-9,770

-874

-66

1,480

-1,572

1,216

-572

-6,727

-1,437

-3,812

-4,380

5,079

-202

Cash Flows From Financing Activities:
Proceeds from (Repayments of) Short-term Debt

131

-543

727

125

-449

244

198

49

-1

-33

-26

-1,688

-33

Issuance of long-term debt

26,778

0

1,488

0

1,268

-

1,489

1,950

-

6

1,683

1,580

0

Repayments of Long-term Debt

9,256

5

1,224

15

1,957

676

597

2,108

78

936

212

229

1,300

Interest rate swap contract terminations

-

-

-

-

-

-105

-20

2

296

146

194

211

0

Issuance of common stock

-

-

-

-

-

288

564

463

601

252

45

5

333

Payments for Repurchase of Common Stock

7,300

320

2,469

231

-

-

433

2,403

1,221

576

-

-

-

Payments of Dividends

2,679

2,613

2,577

2,547

2,477

2,398

2,309

2,286

2,254

2,202

2,483

2,461

2,213

Proceeds from (Payments for) Other Financing Activities

-53

-54

-22

15

-9

-

-

-

-

-

-

-

-

Proceeds from Mead Johnson initial public offering

-

-

-

-

-

-

-

-

-

-

782

-

0

Net Cash Provided by (Used in) Financing Activities

7,621

-3,535

-4,077

-2,653

-3,624

-2,437

-1,068

-4,333

-2,657

-3,343

-17

-2,582

-3,213

Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

-9

-41

52

-33

-95

58

25

-1

-3

14

39

-29

45

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

5,909

1,490

1,184

1,852

-3,186

1,985

1,930

-4,120

743

-2,650

-293

6,175

-217